XIAOMI-W
01810
BABA-W
09988
POP MART
09992
4
BYD COMPANY
01211
5
TENCENT
00700
HK Stock MarketDetailed Quotes
01652 FUSEN PHARM
- 0.290
- 0.0000.00%
Not Open May 7 16:08 CST
214.40MMarket Cap-1.05P/E (TTM)
0.290High0.280Low117.00KVolume0.280Open0.290Pre Close33.57KTurnover0.02%Turnover RatioLossP/E (Static)739.30MShares1.20052wk High0.54P/B214.40MFloat Cap0.23552wk Low--Dividend TTM739.30MShs Float19.975Historical High--Dividend LFY3.45%Amplitude0.235Historical Low0.286Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
FUSEN PHARM Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -42.36%326.03M | -41.65%196.32M | 15.02%565.61M | 103.15%336.44M | 27.51%491.76M | -22.69%165.61M | -20.78%385.66M | -13.45%214.21M | 19.51%486.85M | 26.00%247.5M |
| Operating income | -42.36%326.03M | -41.65%196.32M | 15.02%565.61M | 103.15%336.44M | 27.51%491.76M | -22.69%165.61M | -20.78%385.66M | -13.45%214.21M | 19.51%486.85M | 26.00%247.5M |
| Cost of sales | 38.60%-163.39M | 42.51%-90.45M | 0.24%-266.1M | -83.19%-157.32M | -52.83%-266.74M | 10.53%-85.88M | 20.95%-174.53M | 16.30%-95.98M | -13.28%-220.79M | -27.96%-114.67M |
| Operating expenses | 38.60%-163.39M | 42.51%-90.45M | 0.24%-266.1M | -83.19%-157.32M | -52.83%-266.74M | 10.53%-85.88M | 20.95%-174.53M | 16.30%-95.98M | -13.28%-220.79M | -27.96%-114.67M |
| Gross profit | -45.70%162.64M | -40.89%105.87M | 33.10%299.51M | 124.65%179.12M | 6.58%225.02M | -32.56%79.73M | -20.65%211.13M | -10.99%118.23M | 25.22%266.07M | 24.35%132.83M |
| Selling expenses | 41.95%-81M | 33.98%-52.22M | -17.54%-139.54M | -77.36%-79.09M | -30.54%-118.72M | 12.41%-44.59M | 15.33%-90.95M | 9.76%-50.91M | 4.79%-107.41M | 0.83%-56.42M |
| Administrative expenses | 19.51%-60.29M | -1.28%-36.21M | -36.81%-74.9M | -28.14%-35.76M | 16.08%-54.75M | 11.50%-27.9M | 17.29%-65.24M | 33.98%-31.53M | -34.30%-78.87M | -84.29%-47.76M |
| Research and development expenses | -62.98%-106.26M | -137.47%-57.06M | -329.61%-65.2M | ---24.03M | ---15.18M | ---- | ---- | ---- | ---- | ---- |
| Impairment and provision | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---22.64M | ---- |
| -Goodwill impairment | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---22.64M | ---- |
| Special items of operating profit | 11,814.38%17.4M | 313.44%3.08M | -98.02%146K | -2,431.58%-1.44M | 362.13%7.38M | -100.52%-57K | -159.46%-2.82M | 119.95%11.06M | -81.21%4.73M | -40.77%5.03M |
| Operating profit | -437.29%-67.51M | -194.17%-36.54M | -54.26%20.02M | 440.55%38.8M | -16.07%43.76M | -84.68%7.18M | -15.75%52.14M | 39.10%46.85M | -6.45%61.88M | 3.62%33.68M |
| Financing income | -94.34%24K | -97.47%19K | -78.50%424K | -21.09%752K | -22.91%1.97M | -21.37%953K | 79.01%2.56M | 51.69%1.21M | -60.99%1.43M | -9.62%799K |
| Financing cost | -103.54%-18.86M | -146.41%-7.38M | 47.64%-9.27M | 72.50%-2.99M | -83.29%-17.7M | -53.86%-10.88M | -5.42%-9.66M | -46.37%-7.07M | 13.04%-9.16M | 16.87%-4.83M |
| Share of profits of associates | ---- | -24.45%-1.07M | ---- | 72.27%-859K | 32.52%-9.2M | -62.20%-3.1M | ---13.64M | ---1.91M | ---- | ---- |
| Share of profit from joint venture company | ---- | 97.18%-361K | ---- | -775.85%-12.81M | -201.26%-11.82M | -112.47%-1.46M | -51.88%11.67M | -4.17%11.72M | 434.77%24.25M | --12.23M |
| Special items of earning before tax | -156.26%-104.1M | ---- | -6.88%-40.62M | ---- | -97.13%-38.01M | ---- | ---19.28M | ---- | ---- | ---- |
| Earning before tax | -546.72%-190.45M | -297.96%-45.33M | 4.98%-29.45M | 413.09%22.9M | -230.27%-30.99M | -114.40%-7.31M | -69.66%23.79M | 21.30%50.8M | 22.86%78.41M | 51.87%41.88M |
| Tax | 124.04%1.65M | 229.88%8.38M | -87.03%-6.85M | -2,832.63%-6.45M | 49.00%-3.66M | 103.38%236K | 54.39%-7.18M | 17.27%-6.99M | -36.19%-15.74M | -119.86%-8.45M |
| After-tax profit from continuing operations | -420.18%-188.8M | -324.65%-36.95M | -4.74%-36.3M | 332.40%16.45M | -308.60%-34.65M | -116.15%-7.08M | -73.49%16.61M | 31.05%43.81M | 19.92%62.67M | 40.86%33.43M |
| Earning after tax | -420.18%-188.8M | -324.65%-36.95M | -4.74%-36.3M | 332.40%16.45M | -308.60%-34.65M | -116.15%-7.08M | -73.49%16.61M | 31.05%43.81M | 19.92%62.67M | 40.86%33.43M |
| Minority profit | 5.56%-17K | 11.11%-8K | 63.27%-18K | 77.50%-9K | -53.13%-49K | 63.64%-40K | 99.57%-32K | 92.69%-110K | -535.15%-7.46M | -2,053.25%-1.5M |
| Profit attributable to shareholders | -420.39%-188.78M | -324.48%-36.94M | -4.83%-36.28M | 333.85%16.46M | -307.90%-34.61M | -116.02%-7.04M | -76.27%16.65M | 25.72%43.92M | 31.25%70.13M | 47.68%34.93M |
| Basic earnings per share | -420.00%-0.26 | -350.00%-0.05 | 0.00%-0.05 | 300.00%0.02 | -350.00%-0.05 | -116.67%-0.01 | -77.78%0.02 | 50.00%0.06 | 28.57%0.09 | 33.33%0.04 |
| Diluted earnings per share | -420.00%-0.26 | -350.00%-0.05 | 0.00%-0.05 | 300.00%0.02 | -350.00%-0.05 | -116.67%-0.01 | -77.78%0.02 | 50.00%0.06 | 28.57%0.09 | 33.33%0.04 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.